SCHEMBL213207

SCHEMBL213207

Cc1ccc(N(C(=O)c2nc[nH]c2C(N)=O)c2nc3ccccc3s2)c(C)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 8/20 0.48
KDM4E B2RXH2 5/20 0.47
NPSR1 Q6W5P4 3/20 0.47
HPGD P15428 3/20 0.47
GPR55 Q9Y2T6 1/20 0.47
KMT2A Q03164 2/20 0.46
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.40
SMN1; SMN2 Q16637 4/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
TP53 P04637 2/20 0.38
CASP3 P42574 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
SENP6 Q9GZR1 1/20 0.38
MAPT P10636 3/20 0.36
HTT P42858 1/20 0.36
TSHR P16473 2/20 0.36
ALOX15 P16050 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL215113 0.83 KDM4E (0.43) LMNAKDM4ENPSR1HPGDGPR55
SCHEMBL217227 0.82 POLB (0.37) LMNAKDM4ENPSR1HPGDKMT2A
SCHEMBL214350 0.78 PAX8 (0.36) LMNAKDM4ENPSR1KMT2AALDH1A1
SCHEMBL214851 0.77 SMN1; SMN2 (0.33) LMNAKDM4EKMT2AALDH1A1GAA
SCHEMBL216492 0.75 POLB (0.37) LMNAKDM4ENPSR1HPGDKMT2A
SCHEMBL215550 0.75 MAP2 (0.34) LMNAKDM4EKMT2ASMN1; SMN2TP53
SCHEMBL214403 0.75 ALDH1A1 (0.42) KDM4EKMT2AALDH1A1SMN1; SMN2NPC1
SCHEMBL216235 0.73 KDM4E (0.38) KDM4EHPGDALDH1A1NPC1RAB9A
SCHEMBL213394 0.72 POLB (0.48) LMNAKDM4EKMT2AALDH1A1SMN1; SMN2
SCHEMBL214715 0.72 POLB (0.40) LMNAKDM4ENPSR1HPGDGPR55

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US claimed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US claimed
EP-2061768-A2 IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS Exelixis, Inc. (US) 2009-05-27 EP claimed
WO-2008042282-A2 IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS EXELIXIS, INC. (US) 2008-04-10 WO claimed
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 LMNA 4821/4885KDM4E 952/4885NPSR1 4218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.